Although LXR and Retinoid X receptor (RXR) agonists have proven efficacy to upregulate genes involved in ApoE-lipidation (like ABCA1 or ABCG1), improve Aβ clearance, and reverse memory deficits in animal models of AD, they produce unwanted peripheral effects on triglyceride levels and liver health. Here, ABCG1 is linked to Alzheimer disease.